Novavax Announces Presentation of Phase 3 Data from RSV Maternal Immunization Program at 37th Annual Meeting of the European Society for Pediatric Infectious Diseases
Details are as follows:
Abstract title: | Phase 3 PREPARE study: efficacy and safety of an RSV vaccine administered to pregnant women | ||
Session title: | PIDS/ESPID Joint Plenary Symposium – The future of vaccines (is now) | ||
Session code and track: | ST01; Science track | ||
Location: | Kocka Hall | ||
Date: | Tuesday, May 7 | ||
Time: | 10:30 a.m. ET |
The abstract for the presentation can be found here. In addition, the presentation will be live streamed. For more information, please visit the ESPID meeting’s website.
About ResVax™ and the Prepare Trial
ResVax is an RSV fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant. It is being developed to protect infants from RSV disease via maternal immunization, which may offer the best method of protection from RSV disease in infants through the first months of life. In
About
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contacts:
Investors
[email protected]
240-268-2000
Westwicke
[email protected]
443-213-0506
Media
[email protected]
917-209-7163